SATS Final Programme

L

26th South African Transplantation Society Biennial Congress and Exhibition

The Forum @ Discovery Sandton - South Africa

ON - 2015

X RESS & E

Final Programme 9 - 11 October 2015

ITI

IA

NG

IB

26th BIENN CO

South African Transplantation Society

H

Over time, even subtle changes can add up to real progress. Compared with tacrolimus BID, Advagraf reduces immunosuppression variability1 and non-adherence,*2 and has shown a significant 8% improvement in liver graft survival at 3 years.*3 In transplantation, that’s definitely progress.

* in a large European registry study

Is progress always radical?

S4 ADVAGRAF® 1 mg prolonged-release capsules (1 mg tacrolimus).

S4 ADVAGRAF® 5 mg prolonged-release capsules (5 mg tacrolimus).

Indications: Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicines in adult patients.

Contra-indications: Known hypersensitivity to tacrolimus, the active ingredient in ADVAGRAF®, or other macrolides. Hypersensitivity to any of the excipients of the capsules.

Warnings: Prolonged-release formulations of tacrolimus such as ADVAGRAF® are not interchangeable with immediate-release formulations of tacrolimus, without careful monitoring and supervision by a transplant specialist.

Interactions: ADVAGRAF® is extensively metabolised via the hepatic microsomal cytochrome P-450 system. In particular, ADVAGRAF® showed a broad and powerful inhibitory effect on cytochrome P-450-3A4. ADVAGRAF® is extensively bound to plasma proteins. For this reason, possible interactions with other medicines known to have high affinity for plasma proteins should be considered. During treatment with ADVAGRAF®, vaccinations may be less effective and the use of live attenuated vaccines should be avoided. Care should be taken when using ADVAGRAF® with compounds known to have nephrotoxic effects. When ADVAGRAF® is used together with potentially neurotoxic substances the neurotoxicity of these medicines may be enhanced.

As ADVAGRAF® therapy may be associated with hyperkalaemia or may increase pre-existing hyperkalaemia, high potassium intake or potassiumsaving diuretics should be avoided.

Pregnancy and lactation: ADVAGRAF® is contra-indicated in pregnancy.

Women should not breastfeed whilst receiving ADVAGRAF®. As ADVAGRAF®

may alter the metabolism of oral contraceptives, other forms of contraception should be used.

Dosage and directions for use: ADVAGRAF dose may vary depending upon the immunosuppressive regimen chosen. Dosing should primarily be based on clinical assessments of rejection and tolerability in each patient individually aided by blood level monitoring. It is recommended that the oral daily dose of ADVAGRAF® be administered once daily in the morning, swallowed with fluid (preferably water). It should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption. ®

Side-effects: Ischaemic coronary artery disorders, tachycardia. Anaemia, leukopenia, thrombocytopenia, leukocytosis, abnormal red blood cell analyses.

Tremor, headache. Seizures, disturbances in consciousness, paraesthesias and dysaesthesias, peripheral neuropathies, dizziness, impaired writing, nervous system disorders. Blurred vision, photophobia, eye disorders. Tinnitus.

Dyspnoea, parenchymal lung disorders, pleural effusion, pharyngitis, cough, nasal congestion and inflammation. Diarrhoea, nausea. Gastrointestinal inflammatory conditions, gastrointestinal ulceration and perforation, gastrointestinal haemorrhages, stomatitis and ulceration, ascites, vomiting, gastrointestinal and abdominal pains, dyspeptic signs and symptoms, constipation, flatulence, bloating and distension, loose stools, gastrointestinal signs and symptoms. Renal impairment. Renal failure, acute renal failure, oliguria, renal tubular necrosis, toxic nephropathy, urinary abnormalities, bladder and urethral symptoms. Pruritus, rash, alopecia, acne, increased sweating. Arthralgia, muscle cramps, pain in limb, back pain. Hyperglycaemic conditions, diabetes mellitus, hyperkalaemia. Hypomagnesaemia, hypophosphataemia, hypokalaemia, hypocalcaemia, hyponatraemia, fluid overload, hyperuricaemia, decreased appetite, anorexia, metabolic acidoses, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia,

Astellas Pharma (Pty) Ltd, Reg. No.: 2002/024956/07, EOH Business Park, 5 Osborne Lane, Bedfordview. Tel: (011) 615 9433.

ADV.cycle.ad. 17/04/2015.

other electrolyte abnormalities. Increased risk for infections (viral, bacterial, mycobacterial, fungal, protozoal). Primary graft dysfunction. Hypertension.

Haemorrhage, thrombembolic and ischaemic events, peripheral vascular disorders, vascular hypotensive disorders. Asthenic conditions, febrile disorders, oedema, pain and discomfort, increased blood alkaline phosphatase, increased weight, disturbed body temperature perception. Allergic and anaphylactoid reactions. Hepatic enzymes and function abnormalities, cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis.

Insomnia. Anxiety symptoms, confusion and disorientation, depression, depressed mood, mood disorders and disturbances, nightmare, hallucination, mental disorders.

Registration numbers: ADVAGRAF® 0,5 mg: 42/34/0786; ADVAGRAF® 1 mg: 42/34/0787; ADVAGRAF® 5 mg: 42/34/0788.

Holder of the certificate of registration: Astellas Pharma (Pty) Ltd, Gillooly’s View, 5 Osborne Lane, Bedfordview.

For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority.

References: 1. San’ko-Resmer, J. Boillot O, Wolf P et. al. Renal function, efficacy and safety post conversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. Transplant Int 2012;25(3);283293. 2. Beckebaum S, Speranta Iacob S, Sweid D et. al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from twice-daily tacrolimus-based regimen to once-daily tacrolimus extendedrelease formulation. Transplant Int 2011;24(7):666-675. 3. Adam R, Karam V, Delvartet V et. al. Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry. Am J Transplant 2015(20):1-16. 4. Astellas Pharma (Pty) Ltd. Advagraf Package Insert, 7 December 2012.

CINGULATE 10263

S4 ADVAGRAF® 0,5 mg prolonged-release capsules (0,5 mg tacrolimus).

Information & Organisation

Southern African Transplantation Society SATS is an organization that confers unity to the entire Transplantation Community of South Africa, maintaining the status quo between a diversity of disciplines and transplant centres, creating a forum for discussion and debate. We provide a neutral platform to engage, determine, and implement policy, particularly with respect to controversial issues, as well as providing a link between a variety of institutions and central government, allowing us to communicate with a single voice.

Additionally, we act as a driving force for research, and facilitate continuing medical education and peer review on a regular basis. SATS remains an organization that continues to evolve, forging the platform for transplantation in the years to come.

Executive Committee Dr Elmi Muller Dr Jerome Loveland Prof Russell Britz

President Secretary Past President

Local Organising Committee Jerome Loveland Jean Botha Anna Sparaco Paul Williams Errol Gottlich Russel Britz Trevor Gerntholtz Martin Sussman Mande Toubkin

Chairman Scientific Programme

4

Contents

Information & Organisation

4

Contents

5

Programme at a Glance

7

Scientific Programme

8

Congress Information

11

General Information

12

Exhibition Key

14

Exhibition Floor Plan

15

Notes

17

Sponsors Page

19

5

Netcare Transplant – giving the gift of life and making a difference to the health of our communities.

Netcare VCD 7764 | 09.2015

Programme at a Glance Thursday 8 October 2015 07:30 08:00 08:15

Friday 9 October 2015

Saturday 10 October 2015

Sunday 11 October 2015

Registration

Registration

Registration

Welcome and Opening Remarks

Opening Remarks

Opening Remarks Plenary Session

08:30 Plenary Session

Plenary Session

09:15 10:00

Sponsored by Lagitre International South Africa Pty Ltd

Tea / Coffee Break

10:30 11:00

Plenary Session and Free Communications

11:30 12:00

Plenary Session and Free Communications

Worst Case Ever! / Never Again

12:30 13:00

Lunch Break

14:00

Liver Case Presentation with Expert Panel

14:30 15:00

Kidney / Pancreas Case Presentations with Expert Panel

16:00

Audience Voting Exhibition Build-Up

Soap Box Session Audience Voting South African Transplant Society Annual General Meeting

14:00 – 20:00

17:30

South African Transplant Society Executive Committee Meeting

18:00

At Leisure

19:00

Congress Dinner Sponsored

by Netcare Foundation

17:00

Plenary Session

Tea / Coffee Break

15:30

16:30

Debate Session

7

Cocktail Reception Sponsored by Astellas Pharma

At Leisure

Scientific Programme Friday, 9 October 2015 07:30 – 08:15

Registration

Foyer PLENARY SESSION The Forum Room 2 Chairperson: Jerome Loveland

08:15 – 08:30

Welcome and Opening Remarks

Elmi Muller

08:30 – 09:15

Intestinal Rehabilitation and Transplantation: Working Together to Change the Lives of Children and Adults with Intestinal Failure

David Mercer

09:15 – 10:00

HIV Transplantation: Current Results and The Way Forward

Elmi Muller

10:00 – 10:30

Tea / Coffee Break

Exhibition Area PLENARY SESSION AND FREE COMMUNICATIONS The Forum Room 2 Chairperson: Jerome Loveland and Jean Botha

10:30 – 10:45

Histological Patterns Associated with Late Period Renal Allograft Dysfunction and Loss

10:45 – 11:00

Retrospective Review of Bile Duct Complications Post Liver Transplant in Paediatric Patients Between the Age of 0-16 Years at Wits Donald Gordan Medical Centre Priya Walabh over a ten year period

11:00 – 11:15

Medical Students' Knowledge about Brain Death: A South African Contribution

Sanju Sobnach

11:15 – 11:30

Protecting Liver Grafts from Vascular Complications in Paediatric Liver Transplantation: The Need for Global Peri-operative Approach

Jean de Ville de Goyet

11:30 – 11:45

Utility of Serum Creatinine and Proteinuria in the Evaluation of Late Period Graft Dysfunction

Sara Saffer

11:45 – 12:00

Infection in Paediatric Transplantation

Mignon McCulloch

12:00 – 12:15

Combined Living and Cadaveric Donor Programs: A Successful Strategy for Transplanting Children in an Era of Declining Allocation of PMD Split Liver Grafts

Jean de Ville de Goyet

12:15 – 12:30

Population Profile of Adult Patients Presenting for Orthotopic Liver Transplant (OLTx) at the Wits Donald Gordon Medical Centre (WDGMC)

Bilal Bobat

12:30 – 13:00

mTORi: Mechanism of Action & Appropriate Clinical Use in Renal Transplantation

Josep Campistol

13:00 – 14:00

Lunch Break

2nd Floor

Sara Saffer

LIVER CASE PRESENTATIONS The Forum Room 2 Chairperson: Jerome Loveland 14:00 – 15:00

Liver Case Presentation with Expert Panel

Experts: David Mercer, Russel Britz, Jean de Ville de Goyet

15:00 – 15:30

Tea / Coffee Break

Exhibition Area KIDNEY / PANCREAS CASE PRESENTATIONS The Forum Room 2 Chairperson: Marcus Schamm

15:30 – 16:30

Kidney / Pancreas Case Presentations with Expert Panel

Experts: Vakhtang Rhekviashvilli, Elmi Muller, Trevor Gerntholz

17:00 – 18:00

South African Transplant Society EXCO Meeting

Speaker Preparation Room

19:00

Congress Dinner Sponsored by Netcare Foundation

Adler Museum of Medicine

8

Scientific Programme Saturday, 10 October 2015 07:30 – 08:15

Registration

Foyer PLENARY SESSION The Forum Room 2 Chairperson: Paul Williams

08:15 – 08:30

Opening Remarks

Paul Williams

08:30 – 09:15

Heart Transplantation vs. Mechanical Circulatory Support: Is the Gold Standard Changing

Hermann Reichenspurner

09:15 – 10:00

Ex-vivo Perfusion of Donor Organs and Reconditioning Centres

Paul Corris

10:00 – 10:30

Tea / Coffee Break

Exhibition Area PLENARY SESSION AND FREE COMMUNICATIONS The Forum Room 2 Chairperson: Elmi Muller and Russel Britz

10:30 – 11:00

The Current Status of Lung Transplantation

Hermann Reichenspurner

11:00 – 11:15

Bridging-to-Transplantation by Mechanical Cardiac Support: Current Status in South Africa

Willie Koen

11:15 – 11:30

Lung Transplantation in Johannesburg

Marlize Frauendorf

11:30 – 11:45

Videoscopic Assistance in Mechanical Heart Implantation: A Strategy to Minimize Complications

Willie Koen

11:45 – 12:00

Cardiothoracic Organ Donation

Marlize Frauendorf

12:00 – 12:15

Organ Donation and Transplantation: What do Nurses in Jozi Think?

Kim Crymble

12:15 – 12:30

A 10 Year Retrospective Review of Pre-transplant Tissue Compatibility Testing for Cadaveric transplants at the South African National Blood Service

Kuben Vather

12:30 – 12:45

Renal Allograft Protocol Biopsy: Findings and Clinical Outcomes in Patients at the Charlotte Maxeke Johannesburg Academic Hospital

Fatima Khan

12:45 – 13:00

An Analysis of Reasons why Paediatric Dialysis Patients are Listed for Deceased Donor Transplant at a Tertiary Centre, Johannesburg, South Africa

Tholang Khumalo

13:00 – 14:00

Lunch Break

Exhibition Area PLENARY SESSION The Forum Room 2 Chairperson: Jean Botha

14:00 – 14:30

Treating Chronic Lung Allograft Dysfunction (CLAD) and Bossing BOS

Paul Corris

14:30 – 15:00

Cancer after Renal Transplantation

Josep Campistol

15:00 – 15:30

Tea / Coffee Break

Exhibition Area SOAP BOX SESSION The Forum Room 2 Chairperson: Jerome Loveland

15:30 – 16:30

Soap Box Session and Audience Voting

Russel Britz, Errol Gottlich, Elmi Muller, David Mercer, Michael Morford, David Thompson

16:30 – 17:30

South African Transplant Society Annual General Meeting

The Forum

17:00

Cocktail Reception Sponsored by Astellas Pharma

Exhibition Area

9

Scientific Programme Sunday, 11 October 2015 07:30 – 08:15

Registration

Foyer PLENARY SESSION Sponsored by Lagitre International South Africa Pty Ltd The Forum Room 2 Chairperson: Jerome Loveland

08:15 – 08:30

Opening Remarks

Jerome Loveland

08:30 – 09:15

Transplantation and the Microbiome: An Invisible Frontier

David Mercer

09:15 – 10:00

Anti-HLA Antibodies in Transplantation: Where are we Now?

David Lowe

10:00 – 10:30

Tea / Coffee Break

Exhibition Area DEBATE The Forum Room 2 Moderator: Anna Sparaco

10:30 – 11:15

Money in Organ Donation – Donors Should be Compensated

Jared Falke vs. Graham Paget

11:15 – 12:00

A Diabetic in Renal Failure with a Live Donor: Wait for SPK or Kidney Transplant Now Followed by PAK

Vakhtang Rhekviashvilli vs.

Markus Schamm

12:00 – 13:00

Worst Case Ever! / Never Again

David Mercer, Jean Botha, Anthony Beeton, Martin Sussman

12:00 – 13:00

Lunch Break

Exhibition Area

10

Congress Information Registration Information The Congress Registration Desk at The Forum @ Discovery will be operational during the following hours: 9 October 2015 07h30 – 18h00 10 October 2015 07h30 – 18h00 11 October 2015 07h30 – 14h00

Speaker Preparation 9 October 2015 10 October 2015 11 October 2015

07h30 – 17h00 07h30 – 18h00 07h30 – 14h00

Social Events Congress Dinner Friday, 9th October 2015 Venue: Time: Dress Code:

Adler Museum of Medicine 19h00 for 19h30 Smart Casual

Cocktail Reception Saturday, 10th October 2015 Time: Venue: Dress Code:

17h00 – 19h00 The Atrium @ Discovery Casual

11

General Information Indemnity / Insurance The Congress Organisers have taken reasonable care in making arrangements for the Congress, Exhibition and Social Programme. Neither the Organising Body (SATS), the Local Core Organising Committee, nor its sponsors or committee members assume any responsibility, contractual or delictual for any loss, injury or damage to persons or belongings, or additional expenses incurred as a result of delays or changes in air, rail, sea, road or other services, strikes, sicknesses, weather, or for any acts or omissions by any persons, or for any unforeseen changes to the programme including cancellation of the Congress due to force majeure or any related events or activities. All participants are accordingly advised to make their own arrangements for adequate insurance cover including personal health and travel insurance.

Venue The Forum @ Discovery 16 Fredman Drive Sandton

Parking Limited parking is available at 16 Fredman Drive, Sandton.

Accommodation, Airport Transfers And Tours If you have not already booked your accommodation, please visit the registration desk for assistance. A facility will be available at the registration desk for participants to book transfers from their hotels to the airport for their departures. The cost of a one way transfer is R380.00 per person. If you require assistance with a tour booking, please visit the registration desk.

Safety Johannesburg is like any other major city and has good and bad areas. Common sense will ensure a trouble free and enjoyable Congress.

During the Congress, the registration desk staff and your hotel concierge will be able to assist you with information on places to visit and the appropriate means of transport.

Important Telephone Numbers Congress Organisers Netcare EMRS Police & Flying Squad

083Â 269 0279 082Â 911 10177 10111

12

Hb control is a result of many factors.

You can influence one - The choice of ESA.1 Roche provides you with an ESA choice for the majority of your Chronic Kidney Disease Anaemia patients

When quick correction and effective control with flexible dosing is required 2,3,4

When controlled correction and predictable maintenance over extended dosing intervals is required 5,6,7

ESA = Erythropoiesis Stimulating Agents S4 MIRCERA® 30 µg/0,3 mℓ - 43/8.3/0941; MIRCERA® 50 µg/0,3 mℓ - 42/8.3/0480; MIRCERA® 75 µg/0,3 mℓ - 42/8.3/0481; MIRCERA® 100 µg/0,3 mℓ - 42/8.3/0482; MIRCERA® 120 µg/0,3 mℓ - 43/8.3/0942; MIRCERA® 150 µg/0,3 mℓ - 42/8.3/0483; MIRCERA® 200 µg/0,3 mℓ - 42/8.3/0484; MIRCERA® 250 µg/0,3 mℓ - 42/8.3/0485; MIRCERA® 360 µg/0,6 mℓ - 43/8.3/0943. Each prefilled syringe contains 30 μg, 50 μg, 75 μg, 100 μg, 120 μg,150 μg, 200 μg, 250 μg or 360 μg methoxy polyethylene glycol-epoetin beta. See package insert. S4 RECORMON® 500 IU/0,3 mℓ: 38/8.3/0499. 2 000 IU/0,3 mℓ: 37/8.3/0567.

4 000 IU/0,3 mℓ: 37/8.3/0568. 6 000 IU/0,3 mℓ: 37/8.3/0569. 10 000 IU/0,6 mℓ: 38/8.3/0500. RECORMON® 30 000 IU/0,6 mℓ: 39/8.3/0105. Contains 500 IU, 2 000 IU, 4 000 IU, 6 000 IU, 10 000 IU or 30 000 IU epoetin beta. Please refer to the package insert for full information. Roche Products (Pty) Ltd. www.roche.co.za 846 Mir16/01 References: 1. Barany P, Muller H-J. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant 2007;22(Suppl 4):iv 10-iv 18. doi 10.1093/ ndt/gfm161. 2. Locatelli F, Pozzoni P, Del Vecchio L. Recombinant human epoetin beta in the treatment of renal anemia. Ther Clin Risk Manag 2007;3(3):433-439. 3. Weiss LG, Clyne N, Fihlho JD, et al. The efficacy of once weekly compared to two or three times weekly subcutaneous epoetin B: results from a randomised controlled multicentre trial. Nephrol Dial Transplant 2000;15:2014-2019. 4. Tilkian EE, Tzekov VD, et al. Epoetinbeta (Recormon-Roche) in the treatment of renal anemia in patients with chronic renal failure. Folia Med (Plovdiv) 2000;42(3):11-5. 5. Sulowicz W, Locatelli F, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with Chronic Kidney Disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-646. 6. Klinger M, Arias M, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: A randomized trial. Am J Kid Dis 2007;50(6):989-1000. 7. Saueressig U, Kwan JTC, et al. Healthcare resource utilization for anemia management: Current practice with erythropoiesis stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif 2008;26:537-546.

Exhibition Key

EXHIBITOR

STAND NO.

STAND NO.

EXHIBITOR

Activo Health

8

2

Pharma Dynamics (Pty) Ltd

Astellas Pharma

11 & 12

3

Roche Products (Pty) Ltd

Lagitre International South Africa (Pty) Ltd

6

6

Lagitre International South Africa (Pty) Ltd

Netcare Foundation

9

7

Novartis South Africa (Pty) Ltd

Novartis South Africa (Pty) Ltd

7

8

Activo Health

Pharma Dynamics (Pty) Ltd

2

9

Netcare Foundation

Roche Products (Pty) Ltd

3

10

Sanofi Transplant

Sanofi Transplant

10

11 & 12

Astellas Pharma

14

Exhibition Floor Plan

15

Notes

17

Notes

18

Congress Sponsors

19

Congress Secretariat For further information conact: Gill Slaughter Email: gills@turnergroup.co.za SATS Website: www.sats.org.za